UCLA Trial Uses Stem Cells to Create Renewable Cancer‑Fighting T Cells

Published on OncoDaily via Hung Trinh

In a first‑in‑human trial led by UCLA, researchers demonstrated that hematopoietic stem cells (HSCs) can be engineered to continuously generate tumor‑targeted T cells in patients with solid tumors. The transgenic HSCs carried a TCR specific for NY‑ESO‑1, a tumor antigen, and produced long‑lasting, functional T cell populations without exhaustion or anergy. This dual‑cell therapy approach, combining engineered T cells and HSCs, offers a potential path toward durable immunity in hard‑to‑treat cancers by turning the patient’s body into a renewable source of cancer‑fighting cells.

Read the full article on OncoDaily:

👉 Reprogramming Stem Cells to Create Renewable Cancer-Fighting T Cells

Images used are for illustrative purposes only and do not depict actual persons, products, or facilities. For full detail, refer to the original article via the provided link.